Publications

Nature communications

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

22-06-2020

Cancer chemotherapy and pharmacology

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

01-05-2020

British journal of cancer

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

01-04-2020

Future oncology (London, England)

Vorinostat in patients with resistant BRAF^V600E mutated advanced melanoma: a proof of concept study.

01-04-2020

Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020

Future oncology (London, England)

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

01-02-2020

Translational oncology

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

01-02-2020

Nature cancer

A roadmap for the next decade in cancer research.

01-01-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

01-12-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.

01-12-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

15-11-2019

Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019

Cancer letters

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

01-10-2019

The Journal of molecular diagnostics : JMD

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.

01-09-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Nature cell biology

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

01-06-2019

Cancer research

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

15-05-2019

NPJ breast cancer

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.

25-04-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Molecular & cellular oncology

With great power comes great vulnerability.

14-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018

Molecular & cellular proteomics : MCP

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

01-10-2018

Trends in molecular medicine

An Experimenter's Guide to Glioblastoma Invasion Pathways.

01-09-2018

The Journal of clinical investigation

Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

31-08-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

15-08-2018

Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018

Frontiers of medicine

Taking advantage of drug resistance, a new approach in the war on cancer.

01-08-2018

Cell research

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

01-07-2018

Nature medicine

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

01-07-2018

Cell research

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

01-06-2018

Cell

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

31-05-2018

The EMBO journal

Anti-cancer therapy: senescence is the new black.

15-05-2018

Molecular cancer therapeutics

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

01-04-2018

Hepatology (Baltimore, Md.)

In vivo veritas: Finding novel genes involved in liver cancer through in vivo genetic screens.

01-12-2017

Annals of surgical oncology

Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.

01-12-2017

High-throughput

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

06-11-2017

Cell reports

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

17-10-2017

Breast cancer research : BCR

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

25-08-2017

Cell reports

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

05-07-2017

Breast cancer research and treatment

A breast cancer gene signature for indolent disease.

01-07-2017

European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017

Nature reviews. Clinical oncology

Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

01-06-2017

Nature communications

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

31-05-2017

The New England journal of medicine

Clinical Trials Series — Large Pharma.

06-04-2017

Cell

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

09-02-2017

Biomarker insights

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.

17-12-2016

eLife

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

15-11-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016

The journal of pathology. Clinical research

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.

01-10-2016